HNCIG-2/EORTC 1420 DESIGN AND RATIONALE PUBLISHED IN FRONTIERS

October 22, 2019

Dysphagia is one of the most serious and common adverse events after curative-intent treatment for HNSCC, with huge QOL impact. The EORTC 1420 "Best of" trial is an ongoing open-label phase III prospective randomized trial assessing the "best of" surgery compared to the "best of" RT initially in patients with T1-2N0 OPSCCs, SGSCC, and T1N0 hypopharyngeal SCC. The main objective is to compare patient-reported swallowing function over the first year after randomization between TORS and IMRT. ​ https://www.frontiersin.org/articles/10.3389/fonc.2019.00999/full